Clinical course of SARS‐CoV‐2 infection and recovery in lung transplant recipients
Authors:
- Anil J. TrindadeATAnil J. Trindade
- Kaitlyn C. ChapinKCKaitlyn C. Chapin
- Whitney D. GannonWGWhitney D. Gannon
- Haley HoyHHHaley Hoy
- Caitlin T. DemarestCDCaitlin T. Demarest
- Katie A. McPhersonKMKatie A. McPherson
- Stephanie G. NorfolkSNStephanie G. Norfolk
- Ivan M. RobbinsIRIvan M. Robbins
- Matthew BacchettaMBMatthew Bacchetta
- David B. ErasmusDEDavid B. Erasmus
- Ciara M. ShaverCSCiara M. Shaver
Open Access
- 8 November 2022
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (6) , e13967
Abstract
Background: Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in lung transplant recipients remain limited.Methods: We performed a single‐center, observational study of outcomes in lung transplant recipients diagnosed with SARS‐CoV‐2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.Results: In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre‐Delta, 20 Delta, and 56 Omicron‐era). Twenty‐five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID‐19 did not alter change in forced expiratory volume in 1 s (FEV1) or forced vital capacity (FVC) over time compared to the preceding 6 months. The pre‐COVID FEV1change was −0.05 ml/day (IQR −0.50 to 0.60) compared to −0.20 ml/day (IQR −1.40 to 0.70) post‐COVID (p = .16). The pre‐COVID change in FVC was 0.20 ml/day (IQR −0.60 to 0.70) compared to 0.05 ml/day (IQR −1.00 to 1.10) post‐COVID (p = .76). Although the cohort overall had stable lung function, 33 patients (39%) developed ALAD or accelerated chronic lung allograft dysfunction (FEV1decline >10% from pre‐COVID baseline). Nine patients (35%) with ALAD recovered lung function. Within 3 months of acute COVID infection, 18 patients (17%) developed secondary infections, the majority being bacterial pneumonia. Finally, vaccination with at least two doses of mRNA vaccine was not associated with improved outcomes.Conclusions: This study describes the natural history of SARS‐CoV‐2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS‐CoV‐2 is not associated with worsening lung function. imageKeywords
Funding Information
- National Institutes of Health (K08 HL136888)
This publication has 39 references indexed in Scilit:
- Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejectionThe Journal of Heart and Lung Transplantation, 2020
- Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical StatementAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR)American Journal of Transplantation, 2018
- Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung TransplantationAmerican Journal of Transplantation, 2016
- Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2016
- Antibody-mediated rejectionCurrent Opinion in Organ Transplantation, 2015
- Immunosuppression in lung transplantation2014
- Rhinovirus and other respiratory viruses exert different effects on lung allograft function that are not mediated through acute rejectionClinical Transplantation, 2012
- CXCR3 Chemokine Ligands During Respiratory Viral Infections Predict Lung Allograft DysfunctionAmerican Journal of Transplantation, 2011
- Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung RejectionThe Journal of Heart and Lung Transplantation, 2007